← Back to search

AnaptysBio Inc

ANAB · NASDAQ

Pharmaceutical Preparation Manufacturing

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.

ESG Scores

Overall ESG
6.1
Environmental
6.6
Social
3.6
Governance
6.0

Gender Diversity

Female Directors0.22219999999999998%
CEO GenderMale

Market Data

Price$67.51+0.61 (+0.91%)
Market Cap$1.94B
P/E Ratio—
EPS$—
52W High$73.30
52W Low$17.11
Beta0.47